• Home
  • Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

  • Hengrui Medicine
About Jiangsu Hengrui Medicine Co., Ltd.

     Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. In 1997, it was restructured into a joint-stock company. In 2000 Hengrui was listed on Shanghai Stock Exchange under stock code 600276. The company ranks top 30 worldwide in pharmaceuticals industry by a market capitalization of over 55 billion USD, and is home to more than 21,900 employees worldwide. Hengrui stands out as a front-runner in cancer drugs, contrast agents, ...

Read more Show less
Certifications
  • FDA
    FDA
  • GMP
    GMP
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    China
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    5000+
Company types
Manufacturer/Innovator
Contact info
  • +86 518 851 599 23
  • Website
  • No. 7, Kunlunshan Road,, Economic & Technological, Development Zone,, 222047, Lianyungang, Jiangsu, China
Show contact info Hide contact info
Meet us at

CPHI & PMEC China 2026

Shanghai New International Expo Center
16 Jun 2026 - 18 Jun 2026
View Exhibitor Profile

CPHI Milan 2026

Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
View Exhibitor Profile

Products from Jiangsu Hengrui Medicine Co., Ltd. (100)

  • Sevoflurane Inhalation Anesthetic

    Product Sevoflurane Inhalation Anesthetic

    Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether used as aninhalational anaesthetic for induction and maintenance of general anesthesia.

    Strength: 250ml.


    Sevoflurane Inhalation Anesthetic was approved by NMPA and launc...
  • Desflurane for inhalation

    Product Desflurane for inhalation

    Desflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anesthesia.

    Strength: 240ml

    It is approved by NMPA.
    It is approved by US-FDA and EU.

  • Dexmedetomidine HCl Injection

    Product Dexmedetomidine HCl Injection

    Dexmedetomide HCl is an anxiolytic, sedative, andanalgesic medication.

    Strength: 200mcg/2ml (100mcg/ml); Single-dose Vial
    This product has been approved by CFDA and US-FDA.

    Strength: 80mcg/20ml; 200mcg/50ml; 400mcg/100ml
    This product has been app...
  • Atracurium Besylate

    Product Atracurium Besylate

    Atracurium besylate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxatio...
  • Butorphanol Tartrate

    Product Butorphanol Tartrate

    Butorphanol Tartate is a morphinan-type synthetic opioid analgesic.

    It is approved by NMPA.
  • Salmeterol xinafoate + Fluticasone propionate

    Product Salmeterol xinafoate + Fluticasone propionate

    It is indicated for asthma.It is still in R&D stage.
  • Sugammadex Sodium

    Product Sugammadex Sodium

    Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery in adults.It is still in R&D stage and estimated to be approved by 2020.
  • Paricalcitol

    Product Paricalcitol

    Paricalcitol is a synthetic vitamin D analogue. Paricalcitol has been used to reduce parathyroid hormone levels. It is still in R&D stage, and estimated to be approved by 2020.
  • Ondansetron

    Product Ondansetron

    A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.It is still in R&D stage and estimated to be approved by 2020.
  • Febuxostat

    Product Febuxostat

    Febuxostat is a xanathine oxidase (XO) inhibitor indicated in patients with gout suffering from hyperuricemia and is used in its chronic management.It is still in R&D stage and estimated to be approved by 2020.
  • Capecitabine

    Product Capecitabine

    Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of numerous cancers. It is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body.

    It is approved by NMPA.
  • Caspofungin Acetate

    Product Caspofungin Acetate

    Caspofungin Acetate is a lipopeptide antifungal drug. It is a member of a new class of antifungals termed the echinocandins. It works by inhibiting the enzyme (1→3)-β-D-glucan synthase and thereby disturbing the integrity of the fungal cell wall. Caspofungin was the ...
show all 100 products

Jiangsu Hengrui Medicine Co., Ltd. Resources (3)